A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
← catalyst calendarNCT07527910 · readout in 1,304 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
204estimated
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-22 | actual | When the study began enrolling |
| Primary completion | 2030-03-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-03-15 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions
- Drug: ALN-PNP
- Drug: Tirzepatide — also filed as Zepbound®
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPercent change in liver fat
measured From baseline at week 24
Percent change in liver fat
measured From baseline at week 48
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed